Aim: It is important to assess if clinical trial efficacy translates into real-world effectiveness for COVID-19 vaccines. Materials & methods: We conducted a modified test-negative design (TND) to evaluate the real-world effectiveness of three COVID-19 vaccines. We defined cases in two ways: self-reported COVID-19-positive tests, and self-reported positive tests with ≥1 moderate/severe COVID-19 symptom. Results: Any vaccination was associated with a 95% reduction in subsequently reporting a positive COVID-19 test, and a 71% reduction in reporting a positive test and ≥1 moderate/severe symptom. Conclusion: We observed high effectiveness across all three marketed vaccines, both for self-reported positive COVID-19 tests and moderate/severe COVID-19 symptoms. This innovative TND approach can be implemented in future COVID-19 vaccine and treatment real-world effectiveness studies. Clinicaltrials.gov identifier: NCT04368065. Tweetable abstract Evaluating real-world COVID-19 vaccine effectiveness. #COVID19 #Vaccines #TND #PRO #patientreportedoutcome.
CITATION STYLE
Reynolds, M. W., Secora, A., Joules, A., Albert, L., Brinkley, E., Kwon, T., … Dreyer, N. A. (2022). Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case-control design. Journal of Comparative Effectiveness Research, 11(16), 1161–1172. https://doi.org/10.2217/cer-2022-0069
Mendeley helps you to discover research relevant for your work.